28501006|t|Liquid chromatography-mass spectrometry -based quantitative proteomics analysis reveals chondroprotective effects of astragaloside IV in interleukin-1β - induced SW1353 chondrocyte-like cells
28501006|a|Chondrocyte apoptosis played a key role on the progression of Osteoarthritis (OA). Safe and effective drugs are urgently needed for the treatment of OA. Previous study reported that Astragaloside IV (ASG-IV) had exerted a protective effect against articular cartilage degeneration by promoting rapid proliferation of chondrocyte. Therefore, the aim of our study is to explore the effects and mechanisms of ASG-IV in chondrocyte apoptosis. Isobaric Tags For Relative And Absolute Quantitation (iTRAQ)-based quantitative proteomics was used to quantitatively detect and map proteins in SW1353 chondrocyte-like cells pre-treated with ASG-IV or interleukin-1β (IL-1β) or ASG-IV + IL-1β. The iTRAQ-labeled peptides were fractionated by high-accuracy liquid chromatography-mass spectrometry (LC-MS). Cell apoptosis and differentially expressed proteins was detected by flow cytometry (FCM), quantitative real-time polymerase chain reaction (qRT-PCR), and western blotting, respectively. The apoptosis of the IL-1β - induced SW1353 cells treated with ASG-IV was greatly inhibited. Bioinformatics analysis revealed that gamma actin 1 (ACTG1) and Yes Associated Protein 1 (YAP1), participating in the Hippo signaling pathway and Vitronectin (VTN) and Collagen Type I Alpha 1 Chain (COL1A1), involving in the extracellular matrix (ECM)-receptor interaction signaling pathway, were all significantly up-regulated in the IL-1β - induced SW1353 cells after treatment with ASG-IV. The qRT-PCR and Western blotting results confirmed the up-regulation of these four genes. ASG-IV played a positive role in human osteoarthritic chondrocyte apoptosis, possibly through modulation of the Hippo signaling pathway by up-regulating YAP1 and ACTG1 expression, and also by up-regulating VTN and COL1A1, which are involved in the ECM-receptor interaction pathway. Taken together, all the results suggested that ASG-IV had a novel therapeutic potential for the treatment of OA.
28501006	0	39	Liquid chromatography-mass spectrometry	T059	C0872318
28501006	47	79	quantitative proteomics analysis	T059	C0022885
28501006	60	70	proteomics	T091	C0872252
28501006	88	113	chondroprotective effects	T033	C0243095
28501006	117	133	astragaloside IV	T109,T121	C0378018
28501006	137	151	interleukin-1β	T116,T129	C0021753
28501006	154	161	induced	T169	C0205263
28501006	162	191	SW1353 chondrocyte-like cells	T025	C1516497
28501006	192	203	Chondrocyte	T025	C0225369
28501006	204	213	apoptosis	T043	C0162638
28501006	239	250	progression	T046	C0242656
28501006	254	268	Osteoarthritis	T047	C0029408
28501006	270	272	OA	T047	C0029408
28501006	294	299	drugs	T061	C3687832
28501006	328	337	treatment	T169	C1522326
28501006	341	343	OA	T047	C0029408
28501006	354	359	study	T077	C1706256
28501006	374	390	Astragaloside IV	T109,T121	C0378018
28501006	392	398	ASG-IV	T109,T121	C0378018
28501006	414	431	protective effect	UnknownType	C0678771
28501006	440	472	articular cartilage degeneration	T047	C1394964
28501006	492	505	proliferation	T169	C1514485
28501006	509	520	chondrocyte	T025	C0225369
28501006	548	553	study	T077	C1706256
28501006	572	579	effects	T169	C0728866
28501006	584	594	mechanisms	T169	C0441712
28501006	598	604	ASG-IV	T109,T121	C0378018
28501006	608	619	chondrocyte	T025	C0225369
28501006	620	629	apoptosis	T043	C0162638
28501006	631	721	Isobaric Tags For Relative And Absolute Quantitation (iTRAQ)-based quantitative proteomics	T059	C0022885
28501006	711	721	proteomics	T091	C0872252
28501006	749	755	detect	T033	C0442726
28501006	760	763	map	T052	C1283195
28501006	764	772	proteins	T116,T123	C0033684
28501006	776	805	SW1353 chondrocyte-like cells	T025	C1516497
28501006	806	817	pre-treated	T169	C1522326
28501006	823	829	ASG-IV	T109,T121	C0378018
28501006	833	847	interleukin-1β	T116,T129	C0021753
28501006	849	854	IL-1β	T116,T129	C0021753
28501006	859	865	ASG-IV	T109,T121	C0378018
28501006	868	873	IL-1β	T116,T129	C0021753
28501006	879	901	iTRAQ-labeled peptides	T116	C0030956
28501006	907	919	fractionated	T080	C1979893
28501006	923	976	high-accuracy liquid chromatography-mass spectrometry	T059	C0872318
28501006	978	983	LC-MS	T059	C0872318
28501006	986	1000	Cell apoptosis	T043	C0162638
28501006	1005	1038	differentially expressed proteins	T116,T123	C0033684
28501006	1043	1051	detected	T033	C0442726
28501006	1055	1069	flow cytometry	T059	C0016263
28501006	1071	1074	FCM	T059	C0016263
28501006	1077	1125	quantitative real-time polymerase chain reaction	T063	C3179034
28501006	1127	1134	qRT-PCR	T063	C3179034
28501006	1141	1157	western blotting	T059,T063	C0005863
28501006	1177	1186	apoptosis	T043	C0162638
28501006	1194	1199	IL-1β	T116,T129	C0021753
28501006	1202	1209	induced	T169	C0205263
28501006	1210	1222	SW1353 cells	T025	C1516497
28501006	1223	1230	treated	T169	C1522326
28501006	1236	1242	ASG-IV	T109,T121	C0378018
28501006	1255	1264	inhibited	T080	C0311403
28501006	1266	1280	Bioinformatics	T091	C1140694
28501006	1266	1289	Bioinformatics analysis	T059	C0022885
28501006	1304	1317	gamma actin 1	T116	C3884655
28501006	1319	1324	ACTG1	T116	C3884655
28501006	1330	1354	Yes Associated Protein 1	T116,T123	C1318127
28501006	1356	1360	YAP1	T116,T123	C1318127
28501006	1384	1407	Hippo signaling pathway	T043	C3158583
28501006	1412	1423	Vitronectin	T116,T123	C4281807
28501006	1425	1428	VTN	T116,T123	C4281807
28501006	1434	1463	Collagen Type I Alpha 1 Chain	T116,T123	C0972255
28501006	1465	1471	COL1A1	T116,T123	C0972255
28501006	1491	1556	extracellular matrix (ECM)-receptor interaction signaling pathway	T169	C2984324
28501006	1581	1593	up-regulated	T044	C0041904
28501006	1601	1606	IL-1β	T116,T129	C0021753
28501006	1609	1616	induced	T169	C0205263
28501006	1617	1629	SW1353 cells	T025	C1516497
28501006	1636	1645	treatment	T169	C1522326
28501006	1651	1657	ASG-IV	T109,T121	C0378018
28501006	1663	1670	qRT-PCR	T063	C3179034
28501006	1675	1691	Western blotting	T059,T063	C0005863
28501006	1714	1727	up-regulation	T044	C0041904
28501006	1742	1747	genes	T028	C0017337
28501006	1749	1755	ASG-IV	T109,T121	C0378018
28501006	1765	1778	positive role	T033	C1446409
28501006	1782	1787	human	T016	C0086418
28501006	1788	1824	osteoarthritic chondrocyte apoptosis	T043	C0162638
28501006	1803	1814	chondrocyte	T025	C0225369
28501006	1843	1853	modulation	UnknownType	C0544633
28501006	1861	1884	Hippo signaling pathway	T043	C3158583
28501006	1888	1901	up-regulating	T044	C0041904
28501006	1902	1906	YAP1	T116,T123	C1318127
28501006	1911	1916	ACTG1	T116	C3884655
28501006	1917	1927	expression	T045	C0017262
28501006	1941	1954	up-regulating	T044	C0041904
28501006	1955	1958	VTN	T116,T123	C4281807
28501006	1963	1969	COL1A1	T116,T123	C0972255
28501006	1997	2029	ECM-receptor interaction pathway	T169	C2984324
28501006	2078	2084	ASG-IV	T109,T121	C0378018
28501006	2097	2108	therapeutic	T169	C0302350
28501006	2109	2118	potential	T080	C3245505
28501006	2127	2136	treatment	T169	C1522326
28501006	2140	2142	OA	T047	C0029408